Stock listing
NASDAQ:COYA Coya Therapeutics, Inc. Stock
Home listing (NASDAQ) of Coya Therapeutics, Inc.
Follow Coya Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:COYA
$2.95 USD -0.14 (-4.5%)
Close on Nov 20, 2026
- Day range
- $2.90 – $3.11 USDNov 20, 2026
- Volume
- 138,271 sharesNov 20, 2026
- Market cap
- $69.20M USDAt the close on Nov 20, 2026 · price × 23.46M shares outstanding
- 52-week range
- $2.72 – $6.62 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $615,419 USDMedian day 129,572 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:COYA · Home | $2.95 USD | -0.14 (-4.5%) | 138,271 | $2.94 | $3.11 | $2.90 | $3.09 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:COYA · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $2.95 | -0.14 | -4.5% | $2.94 | $3.11 | $2.90 | 138,271 | |
| $3.09 | +0.07 | +2.3% | $3.03 | $3.30 | $3.01 | 150,403 | |
| $3.02 | +0.02 | +0.7% | $2.99 | $3.12 | $2.93 | 131,274 | |
| $3.00 | -0.13 | -4.2% | $3.175 | $3.175 | $2.962 | 99,179 | |
| $3.13 | -0.14 | -4.3% | $3.25 | $3.25 | $3.02 | 189,167 | |
| $3.27 | +0.06 | +1.9% | $3.19 | $3.41 | $3.05 | 141,124 | |
| $3.21 | +0.05 | +1.6% | $3.29 | $3.39 | $3.17 | 89,965 | |
| $3.16 | -0.17 | -5.1% | $3.23 | $3.47 | $3.15 | 200,524 | |
| $3.33 | +0.34 | +11.4% | $3.00 | $3.38 | $2.925 | 222,818 | |
| $2.99 | +0.18 | +6.4% | $2.83 | $3.025 | $2.735 | 230,567 | |
| $2.81 | -0.27 | -8.8% | $3.03 | $3.14 | $2.72 | 315,215 | |
| $3.08 | -0.03 | -1.0% | $3.28 | $3.40 | $2.98 | 195,395 | |
| $3.11 | -0.12 | -3.7% | $3.26 | $3.405 | $3.03 | 518,217 | |
| $3.23 | -0.38 | -10.5% | $3.64 | $3.89 | $3.175 | 270,174 | |
| $3.61 | -0.37 | -9.3% | $3.96 | $4.085 | $3.594 | 214,740 | |
| $3.98 | -0.08 | -2.0% | $4.08 | $4.20 | $3.95 | 70,105 | |
| $4.06 | -0.06 | -1.5% | $4.09 | $4.175 | $4.045 | 150,844 | |
| $4.12 | +0.17 | +4.3% | $3.97 | $4.30 | $3.94 | 55,827 | |
| $3.95 | +0.01 | +0.3% | $3.95 | $4.03 | $3.91 | 129,572 | |
| $3.94 | -0.20 | -4.8% | $4.08 | $4.245 | $3.935 | 188,644 | |
| $4.14 | 0.00 | 0.0% | $4.09 | $4.43 | $4.09 | 82,988 | |
| $4.14 | -0.07 | -1.7% | $4.23 | $4.29 | $4.10 | 95,099 | |
| $4.21 | +0.01 | +0.2% | $4.22 | $4.38 | $4.21 | 82,913 | |
| $4.20 | -0.05 | -1.2% | $4.29 | $4.535 | $4.20 | 106,480 | |
| $4.25 | -0.09 | -2.1% | $4.37 | $4.39 | $4.16 | 134,191 | |
| $4.34 | +0.16 | +3.8% | $4.18 | $4.50 | $4.14 | 236,556 | |
| $4.18 | -0.295 | -6.6% | $4.645 | $4.645 | $4.16 | 258,003 | |
| $4.475 | -0.335 | -7.0% | $4.81 | $4.89 | $4.45 | 207,772 | |
| $4.81 | -0.14 | -2.8% | $5.00 | $5.05 | $4.81 | 102,055 | |
| $4.95 | -0.04 | -0.8% | $5.00 | $5.05 | $4.85 | 151,829 | |
| $4.99 | +0.08 | +1.6% | $4.91 | $5.00 | $4.70 | 144,420 | |
| $4.91 | +0.06 | +1.2% | $4.81 | $5.01 | $4.755 | 95,511 | |
| $4.85 | 0.00 | 0.0% | $4.86 | $5.03 | $4.74 | 94,629 | |
| $4.85 | +0.04 | +0.8% | $4.85 | $4.94 | $4.78 | 117,247 | |
| $4.81 | +0.08 | +1.7% | $4.80 | $4.93 | $4.76 | 88,690 | |
| $4.73 | -0.28 | -5.6% | $5.00 | $5.00 | $4.70 | 116,132 | |
| $5.01 | -0.02 | -0.4% | $5.06 | $5.15 | $4.98 | 101,360 | |
| $5.03 | +0.05 | +1.0% | $5.02 | $5.05 | $4.93 | 75,465 | |
| $4.98 | -0.10 | -2.0% | $5.03 | $5.12 | $4.96 | 120,318 | |
| $5.08 | -0.10 | -1.9% | $5.19 | $5.24 | $5.02 | 59,938 | |
| $5.18 | +0.14 | +2.8% | $5.02 | $5.18 | $4.92 | 106,635 | |
| $5.04 | -0.26 | -4.9% | $5.31 | $5.31 | $4.90 | 158,612 | |
| $5.30 | +0.35 | +7.1% | $4.99 | $5.35 | $4.93 | 334,121 | |
| $4.95 | +0.06 | +1.2% | $4.94 | $5.04 | $4.831 | 167,197 | |
| $4.89 | +0.13 | +2.7% | $4.76 | $5.085 | $4.705 | 403,456 | |
| $4.76 | +0.30 | +6.7% | $4.54 | $4.89 | $4.54 | 221,539 | |
| $4.46 | -0.19 | -4.1% | $4.66 | $4.719 | $4.46 | 129,322 | |
| $4.65 | +0.01 | +0.2% | $4.62 | $4.72 | $4.49 | 215,172 | |
| $4.64 | +0.26 | +5.9% | $4.39 | $4.78 | $4.33 | 201,468 | |
| $4.38 | -0.14 | -3.1% | $4.59 | $4.66 | $4.37 | 139,342 | |
| $4.52 | -0.09 | -2.0% | $4.61 | $4.62 | $4.455 | 93,464 | |
| $4.61 | 0.00 | 0.0% | $4.55 | $4.695 | $4.53 | 77,819 | |
| $4.61 | -0.15 | -3.2% | $4.82 | $4.82 | $4.595 | 98,353 | |
| $4.76 | +0.21 | +4.6% | $4.54 | $4.77 | $4.52 | 75,759 | |
| $4.55 | +0.13 | +2.9% | $4.50 | $4.58 | $4.36 | 100,315 | |
| $4.42 | -0.09 | -2.0% | $4.53 | $4.649 | $4.39 | 61,902 | |
| $4.51 | -0.05 | -1.1% | $4.52 | $4.63 | $4.48 | 101,246 | |
| $4.56 | -0.03 | -0.7% | $4.58 | $4.698 | $4.51 | 47,432 | |
| $4.59 | -0.27 | -5.6% | $4.82 | $4.82 | $4.55 | 153,108 | |
| $4.86 | -0.01 | -0.2% | $5.14 | $5.14 | $4.76 | 77,622 | |
| $4.87 | -0.17 | -3.4% | $5.02 | $5.03 | $4.83 | 54,399 | |
| $5.04 | +0.08 | +1.6% | $4.99 | $5.22 | $4.98 | 145,185 | |
| $4.96 | +0.09 | +1.8% | $4.89 | $5.26 | $4.71 | 147,065 | |
| $4.87 | +0.01 | +0.2% | $4.90 | $4.95 | $4.805 | 70,948 | |
| $4.86 | -0.11 | -2.2% | $5.00 | $5.00 | $4.73 | 59,524 |
- Ticker
- NASDAQ:COYA
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 10, 2026
Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Latest deck · October 2026
Investor Presentation (October 2026)
Investor deck · 25 slides
Latest news
Coya Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Corporate Update
Nov 10, 2026
Closed $3.16 (-5.1%) on Nov 10, 2026
Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting
Oct 28, 2026
Closed $4.06 (-1.5%) on Oct 28, 2026
Coya to Initiate Open-Label Extension of Phase 2/3 ALSTARS Trial of COYA 302 in ALS
Oct 14, 2026
Closed $4.18 (-6.6%) on Oct 14, 2026
Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference
Oct 13, 2026
Closed $4.48 (-7.0%) on Oct 13, 2026
Coya Therapeutics Announces Completion of Full Enrollment in Phase 2/3 ALSTARS Trial of COYA 302 for the Treatment of ALS
Oct 5, 2026
Closed $4.85 (+0.8%) on Oct 5, 2026
Coya Therapeutics Announces Publication of Preclinical Study Demonstrating Combination Immunomodulatory Effects of COYA 303 in a Well-Established Model of Peripheral and CNS Inflammation
Sep 8, 2026
Closed $4.61 (-3.2%) on Sep 8, 2026
Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update
Aug 11, 2026
Closed $4.80 (+3.4%) on Aug 11, 2026
Coya Therapeutics to Present ALSTARS Trial Design at the ENCALS 2026 Meeting
Jun 18, 2026
Closed $4.92 (-2.2%) on Jun 18, 2026
Coya Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 27 in the last 12 months · 105 in all · newest Nov 10, 2026 · oldest 2023
- Decks
- 24 decks · latest October 2026
Where Coya Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:COYA · Home listing · This page | NASDAQ | United States | USD |
| BOATS:COYA | BOATS | United States | USD |
Valuation
EV/sales 7.1× against a median of 49.9×: 2nd lowest of 7 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $33.40M USD
- P/E
- Loss
- EV/sales
- 7.1×
- EV/EBITDA
- Negative EBITDA
- Price/book
- 2.1×
- Gross margin
- 100.0%
- Operating margin
- −675.3%
- Net margin
- −643.5%
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 1.64
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Coya Therapeutics, Inc. · NASDAQ:COYA | US$69.20M | US$33.40M | n/a | 7.1× | n/a | 2.1× | −643.5% | 0.0× | 1.64 |
| Eastwood Bio-Medical Canada Inc · TSXV:EBM | US$72.06M | US$72.05M | n/a | 127× | n/a | n/a | −28.5% | n/a | 0.56 |
| SynAct Pharma AB · OMXSTO:SYNACT | US$71.20M | US$71.51M | n/a | n/a | n/a | 5.1× | n/a | 0.3× | n/a |
| Bioton S.A. · GPW:BIO | US$70.63M | US$86.88M | n/a | 1.4× | 6.5× | 0.5× | −3.3% | 0.1× | n/a |
| MAIA Biotechnology, Inc. · AMEX:MAIA | US$68.54M | US$68.54M | n/a | n/a | n/a | 4.7× | n/a | 0.0× | 1.62 |
| ABIONYX Pharma SA · EURONEXT:ABNX | US$68.36M | US$55.53M | n/a | 12.4× | n/a | 4.0× | −136.6% | 1.0× | n/a |
| Cingulate Inc. · NASDAQ:CING | US$67.48M | US$1.21B | n/a | n/a | n/a | 3.3× | n/a | 56.0× | 1.41 |
| Energenesis Biomedical Co., Ltd. · TWSE:6657 | US$67.22M | US$47.02M | n/a | 203× | n/a | 3.1× | n/a | 0.0× | n/a |
| MediciNova, Inc. · NASDAQ:MNOV | US$67.11M | US$38.45M | n/a | 41.1× | n/a | 1.6× | n/a | 0.0× | 0.56 |
| Dicot Pharma AB · OMXSTO:DICOT | US$66.56M | US$44.51M | n/a | n/a | n/a | 3.0× | n/a | 0.0× | n/a |
| Cardiff Oncology, Inc. · NASDAQ:CRDF | US$66.34M | US$32.82M | n/a | 58.7× | n/a | 2.4× | n/a | 0.0× | 1.32 |
| Median of the others | US$67.92M | US$62.04M | 49.9× | 6.5× | 3.1× | −28.5% | 0.0× | 1.32 |
Forecasts
7 strong buy · Analysts' consensus from EODHD, read Nov 12, 2026. Not 6ix's view and not investment advice.
- Price target
- 15.21 USD · Analysts' mean
- EPS, year to Dec 2026
- -1.53 · 1 analyst
- Revenue, year to Dec 2026
- 1.14M · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Arun Swaminathan | Chief Executive Officer |
| David Snyder | Chief Financial Officer & Chief Operating Officer |
| Fred Grossman | President & Chief Medical Officer |
| Daniel Barvin | Vice President of Operations & Patient Advocacy |
| Karen King | Senior VP of Program Management & Clinical Operations |
| Michelle Frazier | Senior VP of Regulatory |
| Anabella Villalobos | Chief Scientific Officer at Metaphore Biotechnologies |
| Ann Lee | Chief Technical Officer at Prime Medicine |
Board
| Director | Role |
|---|---|
| Dieter Weinand | Chairman of the Board of Directors |
| Mark Pavao | Director |
| Wilbur Ross | Director |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 10, 2026 · Before open | −5.1% |
| Q2 2026 | Aug 11, 2026 · Before open | +3.5% |
| Q1 2026 | May 7, 2026 | −3.1% |
| Q4 2025 | Mar 16, 2026 · Before open | −0.7% |
| Q3 2025 | Nov 12, 2025 · Before open | +1.3% |
| Q2 2025 | Aug 12, 2025 · Before open | −0.3% |
| Q1 2025 | May 13, 2025 · Before open | −6.2% |
| Q4 2024 | Mar 18, 2025 | −5.8% |
| Q3 2024 | Nov 6, 2024 · Before open | +7.7% |
| Q2 2024 | Aug 12, 2024 · Before open | −12.9% |
All 17 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 9, 2024 | +2.2% |
| Q4 2023 | Mar 19, 2024 · Before open | +2.1% |
| Q3 2023 | Nov 8, 2023 · Before open | −0.1% |
| Q2 2023 | Aug 8, 2023 · Before open | +1.3% |
| Q1 2023 | May 10, 2023 · Before open | +1.9% |
| Q4 2022 | Mar 29, 2023 · After close | −4.5% |
| Q3 2022 | Dec 30, 2022 · After close | −1.9% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (October 2026) | Investor deck | 25 slides | October 2026 |
| Investor Presentation (September 2026) | Investor deck | 25 slides | September 2026 |
| Investor Presentation (August 2026) | Investor deck | 25 slides | August 2026 |
| Investor Presentation (July 2026) | Investor deck | 18 slides | July 2026 |
| Investor Presentation (June 2026) | Investor deck | 36 slides | June 2026 |
| Investor Presentation (May 2026) | Investor deck | 36 slides | May 2026 |
| Investor Presentation (April 2026) | Investor deck | 36 slides | April 2026 |
| Investor Presentation (March 2026) | Investor deck | 36 slides | March 2026 |
| Investor Presentation (February 2026) | Investor deck | 34 slides | February 2026 |
| Investor Presentation (January 2026) | Investor deck | 43 slides | January 2026 |
All 24 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (July 2025) | Investor deck | 54 slides | July 2025 |
| Investor Presentation (March 2025) | Investor deck | 40 slides | March 2025 |
| Investor Presentation (January 2025) | Investor deck | 37 slides | January 2025 |
| Clinical Trials on Alzheimer's Disease Conference (CTAD24) 2024 | Conference | 16 slides | Oct 29, 2024 |
| Investor Presentation (April 2024) | Investor deck | 38 slides | April 2024 |
| Investor Presentation (February 2024) | Investor deck | 37 slides | February 2024 |
| 5th Exosome Based Therapeutics Summit (November 2023) | Conference | 25 slides | Nov 8, 2023 |
| Investor Presentation (October 2023) | Investor deck | 31 slides | October 2023 |
| Technical Presentation (June 2023) | Technical | 9 slides | Jun 7, 2023 |
| Investor Presentation (June 2023) | Investor deck | 31 slides | June 2023 |
| Investor Presentation (May 2023) | Investor deck | 24 slides | May 2023 |
| Investor Presentation (May 2023) | Investor deck | 29 slides | May 2023 |
| 2023 MDA Clinical & Scientific Conference | Conference | 18 slides | Mar 21, 2023 |
| IPO Roadshow (December 2022) | IPO roadshow | 25 slides | Dec 6, 2022 |
Financings
| Raise | Date |
|---|---|
| Private placement of common stock Announced: about US$11.1M · US$4.4 a share Buyers: Dr. Reddy’s Laboratories, Inc. ($10 million); Greenlight Capital ($1.1 million) Use of proceeds: Accelerate tech transfer and scale-up manufacturing of low dose IL-2 to support commercial readiness of COYA 302 | Jan 30, 2026 |
| Public offering of common stock Closed: US$23M raised · US$5.5 a share · Lucid Capital Markets +1 Dealers: Lucid Capital Markets (lead), Allele Capital Partners, LLC Use of proceeds: Working capital and general corporate purposes, including funding its clinical development plan | Oct 27, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$5.00 a share on Dec 28, 2022.
- Price
- US$5.00 a share
- Shares offered
- 3,050,000 shares of common stock
- Offering size
- US$15.3 million
- Underwriters' option
- Up to 290,000 more shares
- Listing
- COYA on the Nasdaq Capital Market
- Underwriters
- Chardan, Newbridge Securities Corporation, Joseph Gunnar & Co., LLC · In the order on the cover
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Aug 19, 2022 |
| Filed publicly | Nov 18, 2022 |
| Amended twice | Newest Dec 13, 2022 |
| Shares registered with an exchange | Dec 27, 2022 |
| Declared effective by the SEC | Dec 28, 2022 |
| Final prospectus, with the price | Dec 30, 2022 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Dec 30, 2022 |
| CERT · Exchange's certificate of listing | Dec 29, 2022 |
| EFFECT · Notice that a registration is effective | Dec 28, 2022 |
| 8-A12B · Registration of shares for listing on an exchange | Dec 27, 2022 |
| CORRESP · Letter to the SEC | Dec 23, 2022 |
| CORRESP · Letter to the SEC | Dec 23, 2022 |
| CORRESP · Letter to the SEC | Dec 13, 2022 |
| S-1/A · Registration statement, amended | Dec 13, 2022 |
| UPLOAD · Letter from the SEC | Dec 9, 2022 |
| FWP · Free writing prospectus | Dec 6, 2022 |
All 23 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Dec 5, 2022 |
| S-1/A · Registration statement, amended | Dec 5, 2022 |
| UPLOAD · Letter from the SEC | Nov 29, 2022 |
| CORRESP · Letter to the SEC | Nov 18, 2022 |
| S-1 · Registration statement | Nov 18, 2022 |
| UPLOAD · Letter from the SEC | Nov 4, 2022 |
| DRSLTR · Letter to the SEC with a draft | Oct 28, 2022 |
| DRS/A · Draft registration statement, amended | Oct 28, 2022 |
| UPLOAD · Letter from the SEC | Oct 19, 2022 |
| DRSLTR · Letter to the SEC with a draft | Oct 7, 2022 |
| DRS/A · Draft registration statement, amended | Oct 7, 2022 |
| UPLOAD · Letter from the SEC | Sep 15, 2022 |
| DRS · Draft registration statement | Aug 19, 2022 |
Open IPO · From the cover of the final prospectus (424B4) filed Dec 30, 2022
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 7.95M | 3.55M | 6.00M | 0 | 0 | |
| Cost of revenue | 27.4K | 11.9M | 5.50M | 4.41M | 16.1K | |
| Gross profit | 7.92M | -8.31M | 500.7K | -4.41M | -16.1K | |
| Research and development | 16.7M | 11.9M | 5.50M | 4.41M | 2.54M | 373.5K |
| Selling, general and administrative | 11.4M | 8.89M | 7.83M | 4.85M | 2.31M | 668.7K |
| Operating income | -22.6M | -17.2M | -7.90M | -9.81M | -4.87M | -1.04M |
| Depreciation and amortization | 27.4K | 27.4K | 27.4K | 27.4K | 16.1K | 704.7K |
| EBITDA | -22.5M | -17.2M | -7.88M | -9.78M | -4.85M | -337.5K |
| Interest expense | 2.43M | 21.5K | 39.0K | |||
| Income before tax | -21.2M | -15.6M | -7.26M | -12.2M | -4.89M | -1.10M |
| Income tax | 3.09K | -720.3K | 723.9K | 0 | -21.5K | -704 |
| Net income | -21.2M | -14.9M | -7.99M | -12.2M | -4.89M | -1.10M |
| Earnings per share, basic | -1.27 | -0.98 | -0.79 | -4.73 | -1.89 | -0.42 |
| Earnings per share, diluted | -1.27 | -0.98 | -0.79 | -4.73 | -1.89 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 46.8M | 38.3M | 32.6M | 5.93M | 4.34M | 8.72M |
| Short-term investments | 38.3B | |||||
| Receivables | 730.6K | 7.50M | 1.00K | |||
| Current assets | 49.9M | 44.3M | 41.2M | 7.18M | 4.58M | 8.75M |
| Property, plant and equipment | 11.2K | 38.6K | 65.9K | 93.3K | 120.7K | |
| Total assets | 50.0M | 44.3M | 41.3M | 8.40M | 4.79M | 8.75M |
| Accounts payable | 1.06M | 1.59M | 1.16M | 1.82M | 857.6K | 447.1K |
| Current liabilities | 5.87M | 3.82M | 5.05M | 3.82M | 1.15M | 447.1K |
| Long-term debt | 13.0M | |||||
| Total debt | 13.0M | |||||
| Total liabilities | 6.92M | 4.77M | 5.63M | 16.8M | 1.15M | 447.1K |
| Shareholders' equity | 43.0M | 39.6M | 35.6M | -8.39M | 3.64M | 8.30M |
| Shares outstanding | 20.9M | 16.7M | 14.4M | 2.59M | 2.59M | 2.59M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -10.7M | -10.3M | -11.2M | -7.24M | -3.90M | -391.3K |
| Capital spending | 0 | 0 | -1 | -4 | -136.8K | -4 |
| Free cash flow | -10.7M | -10.3M | -11.2M | -7.24M | -4.04M | -391.3K |
| Cash from investing | -1.16M | -25.0K | -543.2K | -525.0K | -136.8K | -136.8K |
| Cash from financing | 20.4M | 16.0M | 38.4M | 9.36M | -340.6K | 9.11M |
| Change in cash | 8.48M | 5.71M | 26.7M | 1.59M | -4.38M | 8.72M |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 10, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 10, 2026 | Results | SEC |
| 8-K · Current report | Oct 14, 2026 | Current report | SEC |
| 8-K · Current report | Oct 5, 2026 | Current report | SEC |
| 8-K · Current report | Sep 15, 2026 | Current report | SEC |
| 10-Q · Quarterly report | Aug 11, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 11, 2026 | Results | SEC |
| 8-K/A · Current report, amended | Aug 7, 2026 | Management or board change | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 27, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jun 25, 2026 | Meeting outcome | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| ARS · Annual report to shareholders | May 13, 2026 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 13, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 13, 2026 | Meeting notice | SEC |
| 8-K · Current report | May 12, 2026 | Material contract | SEC |
| 424B5 · Prospectus | May 12, 2026 | Offer document | SEC |
| 10-Q · Quarterly report | May 12, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 12, 2026 | Results | SEC |
| 4 · Change in ownership | Apr 9, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Apr 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Apr 2, 2026 | Management or board change | SEC |
| EFFECT · Notice that a registration is effective | Mar 23, 2026 | Other filings | SEC |
| 424B3 · Prospectus | Mar 20, 2026 | Offer document | SEC |
| CORRESP · Letter to the SEC | Mar 19, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Mar 19, 2026 | Other filings | SEC |
| S-3 · Registration statement | Mar 16, 2026 | Offer document | SEC |
| 10-K · Annual report | Mar 16, 2026 | Annual report | SEC |
| 8-K · Current report | Mar 16, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Mar 12, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 30, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 30, 2026 | Material contract | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jan 28, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 26, 2026 | Insider trade | SEC |
| 8-K · Current report | Jan 20, 2026 | Current report | SEC |
| 8-K · Current report | Jan 8, 2026 | Current report | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Dec 17, 2025 | Current report | SEC |
| 10-Q · Quarterly report | Nov 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Nov 12, 2025 | Results | SEC |
| 8-K · Current report | Oct 27, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Oct 27, 2025 | Offer document | SEC |
| 424B5 · Prospectus | Oct 23, 2025 | Offer document | SEC |
| 8-K · Current report | Sep 2, 2025 | Current report | SEC |
| EFFECT · Notice that a registration is effective | Aug 20, 2025 | Other filings | SEC |
| 424B7 · Prospectus | Aug 19, 2025 | Offer document | SEC |
| 4 · Change in ownership | Aug 19, 2025 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Aug 18, 2025 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Aug 13, 2025 | Other filings | SEC |
| S-3 · Registration statement | Aug 12, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | Aug 12, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2025 | Results | SEC |
| 8-K · Current report | Jul 29, 2025 | Current report | SEC |
| 8-K · Current report | Jul 1, 2025 | Current report | SEC |
| 8-K · Current report | Jun 26, 2025 | Meeting outcome | SEC |
| ARS · Annual report to shareholders | May 16, 2025 | Annual report | SEC |
| DEFA14A · Additional proxy material | May 16, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | May 16, 2025 | Meeting notice | SEC |
| 10-Q · Quarterly report | May 13, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 13, 2025 | Results | SEC |
| 10-K/A · Annual report, amended | Apr 28, 2025 | Annual report | SEC |
| 10-K · Annual report | Mar 18, 2025 | Annual report | SEC |
| 8-K · Current report | Mar 18, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Feb 25, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 10, 2025 | Big-stake notice | SEC |
| S-8 · Registration statement for employee plans | Jan 30, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Dec 2, 2024 | Other filings | SEC |
| 424B3 · Prospectus | Nov 29, 2024 | Offer document | SEC |
| CORRESP · Letter to the SEC | Nov 26, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Nov 25, 2024 | Other filings | SEC |
| S-3 · Registration statement | Nov 20, 2024 | Offer document | SEC |
| 4 · Change in ownership | Nov 14, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 12, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 12, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 6, 2024 | Results | SEC |
| 8-K · Current report | Nov 5, 2024 | Management or board change | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 4, 2024 | Big-stake notice | SEC |
| 8-K · Current report | Oct 31, 2024 | Management or board change | SEC |
| 8-K · Current report | Oct 29, 2024 | Current report | SEC |
| D | Oct 28, 2024 | Other filings | SEC |
| 8-K · Current report | Oct 22, 2024 | Material contract | SEC |
| 3 · Initial statement of ownership | Aug 20, 2024 | Insider trade | SEC |
| 8-K · Current report | Aug 19, 2024 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 12, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 12, 2024 | Results | SEC |
| 8-K · Current report | Jul 15, 2024 | Current report | SEC |
| 424B3 · Prospectus | Jun 24, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jun 24, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jun 20, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jun 18, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jun 14, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 5, 2024 | Material contract | SEC |
| 8-K · Current report | May 20, 2024 | Material contract | SEC |
| 10-Q · Quarterly report | May 9, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 9, 2024 | Results | SEC |
| 8-K · Current report | May 8, 2024 | Management or board change | SEC |
| DEFA14A · Additional proxy material | Mar 28, 2024 | Meeting notice | SEC |
| ARS · Annual report to shareholders | Mar 28, 2024 | Annual report | SEC |
| DEFA14A · Additional proxy material | Mar 28, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Mar 28, 2024 | Meeting notice | SEC |
| 10-K · Annual report | Mar 19, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 19, 2024 | Results | SEC |
| 4 · Change in ownership | Mar 5, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 7, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Feb 2, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 19, 2024 | Insider trade | SEC |
| 8-K · Current report | Jan 19, 2024 | Current report | SEC |
| 424B3 · Prospectus | Jan 16, 2024 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | Jan 16, 2024 | Other filings | SEC |
| CORRESP · Letter to the SEC | Jan 10, 2024 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Jan 9, 2024 | Other filings | SEC |
| S-3 · Registration statement | Jan 4, 2024 | Offer document | SEC |
| 4 · Change in ownership | Jan 4, 2024 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 29, 2023 | Insider trade | SEC |
| D | Dec 20, 2023 | Other filings | SEC |
| 8-K · Current report | Dec 20, 2023 | Management or board change | SEC |
| SC 13G · Big-stake notice | Dec 12, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Dec 6, 2023 | Material contract | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Nov 8, 2023 | Results | SEC |
| 4 · Change in ownership | Aug 21, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Aug 21, 2023 | Insider trade | SEC |
| 8-K · Current report | Aug 21, 2023 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 8, 2023 | Quarterly report | SEC |
| 8-K · Current report | Aug 8, 2023 | Results | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jul 19, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 14, 2023 | Management or board change | SEC |
| 8-K · Current report | Jul 10, 2023 | Management or board change | SEC |
| 8-K · Current report | Jun 29, 2023 | Meeting outcome | SEC |
| 8-K · Current report | Jun 12, 2023 | Current report | SEC |
| 8-K · Current report | May 23, 2023 | Current report | SEC |
| DEFA14A · Additional proxy material | May 19, 2023 | Meeting notice | SEC |
| ARS · Annual report to shareholders | May 19, 2023 | Annual report | SEC |
| DEF 14A · Proxy statement | May 19, 2023 | Meeting notice | SEC |
| 8-K · Current report | May 16, 2023 | Current report | SEC |
| 424B4 · Prospectus | May 12, 2023 | Offer document | SEC |
| EFFECT · Notice that a registration is effective | May 11, 2023 | Other filings | SEC |
| 10-Q · Quarterly report | May 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 10, 2023 | Results | SEC |
| POS AM · Amendment to an effective registration | May 8, 2023 | Offer document | SEC |
| 10-K/A · Annual report, amended | May 1, 2023 | Annual report | SEC |
| S-8 · Registration statement for employee plans | Apr 14, 2023 | Offer document | SEC |
| 10-K · Annual report | Mar 29, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 29, 2023 | Results | SEC |
| 8-K · Current report | Mar 22, 2023 | Material contract | SEC |
| 8-K · Current report | Mar 21, 2023 | Current report | SEC |
| 8-K · Current report | Mar 13, 2023 | Current report | SEC |
| 8-K · Current report | Mar 1, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 1, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 14, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 14, 2023 | Big-stake notice | SEC |
| 8-K · Current report | Jan 25, 2023 | Current report | SEC |
| 4/A · Change in ownership, amended | Jan 17, 2023 | Insider trade | SEC |
| SC 13G · Big-stake notice | Jan 5, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 4, 2023 | Insider trade | SEC |
| 424B4 · Prospectus | Dec 30, 2022 | Offer document | SEC |
| CERT · Exchange's certificate of listing | Dec 29, 2022 | Other filings | SEC |
| SEC STAFF LETTER | Dec 29, 2022 | Other filings | SEC |
This page holds 200 of 232 filings. Open Filings
Cap table
Built by 6ix from Coya Therapeutics, Inc.’s releases · as of Nov 5, 2026
- Common shares
- 23,457,849
- Fully diluted
- 23,457,849
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 23,457,849 | Nov 5, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Nov 5, 2026 | 23,457,849 |
| Sep 30, 2026 | 23,457,849 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Wilbur L Ross Jr Other companies: Taronis Fuels Inc (Director · Jun 4, 2021 – Jun 4, 2021 · Past); Ross Acquisition II Corp (Chief Executive Officer, Director · Mar 11, 2021 – Mar 11, 2021 · Past) | Director · Since at least Dec 19, 2023 |
| David Snyder Other companies: Exicure, Inc. (Chief Financial Officer · Mar 12, 2020 – Mar 12, 2020 · Past) | Chief Financial Officer & Chief Operating Officer · Since at least Dec 28, 2022 |
| Hideki Garren Other companies: Prothena Corporation plc (Chief Medical Officer · Apr 5, 2021 – Feb 27, 2024 · Past) | Director · Dec 28, 2022 – Jan 1, 2024 · Past |
| Adrian Hepner | Chief Medical Officer · Dec 28, 2022 – Feb 27, 2023 · Past |
| Anabella Villalobos | Director · Since at least Jan 2, 2026 |
| Ann Lee | Director · Since at least Aug 22, 2023 |
| Arun Swaminathan | Chief Executive Officer, Director · Since at least Aug 19, 2024 |
| Daniel Barvin | Vice President of Operations & Patient Advocacy · Since at least Nov 4, 2026 |
| Dieter Weinand | Chairman of the Board of Directors · Since at least Apr 2, 2026 |
| Dov Goldstein | Until Jun 18, 2026 · Past |
All 16 people
| Person | Seat |
|---|---|
| Fred Grossman | Chief Medical Officer · Since at least Jan 22, 2026 |
| Fred Grossman | President & Chief Medical Officer · Since at least Oct 28, 2026 |
| Karen King | Senior VP of Program Management & Clinical Operations · Since at least Oct 28, 2026 |
| Mark Pavao | Director · Since at least Apr 1, 2026 |
| Michelle Frazier | Senior VP of Regulatory · Since at least Nov 4, 2026 |
| Wilbur Ross | Director · Since at least Nov 4, 2026 |
Log in to ask 6ix AI your own questions about Coya Therapeutics, Inc.